Login Register Cart 0
Generic placeholder image

Coronaviruses

Editor-in-Chief

ISSN (Print): 2666-7967
ISSN (Online): 2666-7975

Back
Journal Home About Journal Editorial Board Current Issue Volumes/Issues
Subscribe
HIGHLIGHTS

Potential Mitigation, Prophylactics, and Treatments to Overcome COVID- 19

Author(s): Prabagaran Narayanasamy*

Volume 2, Issue 2, 2021

Published on: 20 September, 2020

Page: [135 - 137] Pages: 3

DOI: 10.2174/2666796701999200921094712

Abstract

SARS-CoV-2 can naturally grow and spread from bats or rodents. There are different ways to protect oneself from such viruses. Firstly, a thorough diagnosis by different methods of testing, isolating the infected, and phased interaction with people are advanced, societal-level mitigative efforts that could be implemented. Another method of protection is to eat healthy food. Spices contain flavonoids, acetaminophen, and pseudoephedrine; these ingredients are natural and non-steroidal anti-inflammatory agents and cause no harm. Meat that is mildly spiced, and eggs are also good to boost the immune system. Thirdly, herd immunity is a way to protect people from the virus. Around 50,000 infections in a 250-mile radius could help to develop herd immunity, but this is only a prediction. One should visit his physician if he has a high temperature or cough. SARS-CoV-2, which causes COVID-19, is a new viral strain containing genetic sequences from HIV and malaria in addition to the SARS virus. COVID-19 also targets the ACE2 receptor, which is present in the lungs, heart, and kidneys. Remdesivir seems to be lowering the viral growth in some clinical studies, and in some conditions, it is still understudied and ineffective to eradicate the virus. Recent reports predicted that around 15 COVID-19 mutants have arisen in the last 5 months. The new mutants could be more active or less active, or even drug-resistant. And lastly, new vaccines or drugs must be discovered or invented in BSL3 labs. COVID-19 can be overcome by following mitigation, prophylaxis, and treatment.

Keywords: Mitigation, prophylactics, treatment, death, cure, COVID-19, SARS-CoV-2.

[1]
Frandsen J, Choi SR, Narayanasamy P. Neural glyoxalase pathway enhancement by morin derivatives in an Alzheimer’s disease model. ACS Chem Neurosci 2020; 11(3): 356-66.
[http://dx.doi.org/10.1021/acschemneuro.9b00566] [PMID: 31909963]
[2]
Coutard B, Valle C, de Lamballerie X, Canard B, Seidah NG, Decroly E. The spike glycoprotein of the new coronavirus 2019-nCoV contains a furin-like cleavage site absent in CoV of the same clade. Antiviral Res 2020; 176104742
[http://dx.doi.org/10.1016/j.antiviral.2020.104742] [PMID: 32057769]
[3]
Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 2020; 181: 271-80.
[4]
Shang J, Wan Y, Liu C, et al. Structure of mouse coronavirus spike protein complexed with receptor reveals mechanism for viral entry. PLoS Pathog 2020; 16(3)e1008392
[http://dx.doi.org/10.1371/journal.ppat.1008392] [PMID: 32150576]
[5]
Yang TJ, Chang YC, Ko TP, et al. Cryo-EM analysis of a feline coronavirus spike protein reveals a unique structure and camouflaging glycans. Proc Natl Acad Sci USA 2020; 117(3): 1438-46.
[http://dx.doi.org/10.1073/pnas.1908898117] [PMID: 31900356]
[6]
Wang M, Cao R, Zhang L, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res 2020; 30(3): 269-71.
[http://dx.doi.org/10.1038/s41422-020-0282-0] [PMID: 32020029]
[7]
Lin SM, Lin SC, Hsu JN, et al. Structure-based stabilization of non-native protein-protein interactions of coronavirus nucleocapsid proteins in antiviral drug design. J Med Chem 2020; 63(6): 3131-41.
[http://dx.doi.org/10.1021/acs.jmedchem.9b01913] [PMID: 32105468]
[8]
Zhang L, Lin D, Kusov Y, et al. α-Ketoamides as broad-spectrum inhibitors of coronavirus and enterovirus replication: structure-based design, synthesis, and activity assessment. J Med Chem 2020; 63(9): 4562-78.
[http://dx.doi.org/10.1021/acs.jmedchem.9b01828] [PMID: 32045235]
[9]
Choi SR, Britigan BE, Narayanasamy P. Treatment of virulent Mycobacterium tuberculosis and HIV coinfected macrophages with gallium nanoparticles inhibits pathogen growth and modulates macrophage cytokine production. MSphere 2019; 4(4): 4.
[http://dx.doi.org/10.1128/mSphere.00443-19] [PMID: 31341073]
[10]
Tian M, McGovern K, Cheng HL, et al. Conditional antibody expression to avoid central B cell deletion in humanized HIV-1 vaccine mouse models. Proc Natl Acad Sci USA 2020; 117(14): 7929-40.
[http://dx.doi.org/10.1073/pnas.1921996117] [PMID: 32209668]

Rights & Permissions Print Cite
Article Metrics
12
1
© 2024 Bentham Science Publishers | Privacy Policy